Clinical Trial

A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a multicenter, randomized, double-blind, parallel-controlled, phase III clinical trial to evaluate efficacy and safety of the triple combination therapy of prusogliptin, dapagliflozin and metformin in subjects with type 2 diabetes who have inadequate glycemic control on metformin alone.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-10; most recent amendment 2026-04-03.
Status change: Enrolling by Invitation → Active, Not Recruiting 2026-04-03
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-09-25
Trial Details
NCT Number NCT07026968
Lead Sponsor CSPC Ouyi Pharmaceutical Co., Ltd.
Conditions Type 2 Diabetes
Enrollment 815 participants
Start Date 2025-06-20
Primary Completion 2026-10-30 (estimated)
Study Completion 2026-11-13 (estimated)
Updated on ClinicalTrials.gov 2026-04-06